Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Technology appraisal guidance
Reference number: TA333
Published: 25 February 2015

Renal cell carcinoma (advanced) - axitinib: manufacturer additional evidence, updated basecase and PAS

Renal cell carcinoma (advanced) - axitinib: manufacturer additional evidence, updated basecase and PAS

Renal cell carcinoma (advanced) - axitinib: manufacturer additional evidence, updated basecase and PAS
28 March 2013
(127.02 Kb 36 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 28 March 2013